Yao Zhu, MD, PhD, presented “Epidemiology & Genomics of Prostate Cancer in Asian Men” for the Grand Rounds in Urology audience in June, 2020.


How to cite: Zhu, Yao. “Epidemiology & Genomics of Prostate Cancer in Asian Men” June, 2020. Accessed Nov 2024. https://grandroundsinurology.com/epidemiology-genomics-of-prostate-cancer-in-asian-men/

Epidemiology & Genomics of Prostate Cancer in Asian Men – Summary:

In conversation with Peter K.F. Chiu, MD, PhD, FRCSEd, Honorary Clinical Assistant Professor and Associate Consultant in the Division of Urology at the Chinese University of Hong Kong, Yao Zhu, MD, PhD, attending urologist at Fudan University Shanghai Cancer Center and Associate Professor in Oncology at Shanghai Medical College, discusses the increasing number of deaths from prostate cancer in East Asia, emphasizing the need to develop Asian-specific genetic risk models. Dr. Zhu notes that while data on non-Western populations has been relatively limited to this point, there appear to be numerous differences in prostate cancer-related mutations between East Asian men and Western men, including lower rates of TMPRSS2-ERG fusion and PTEN deletion, and increased prevalence of FOXA1, SPOP, CHD1, and BRCA2. He also observes that there are pharmacogenomic implications to differences in testosterone metabolism-related genes between East Asian and Western men.

For more information on genetic & genomic testing for prostate cancer, visit our Next Generation Learning Center.

ABOUT THE AUTHOR

+ posts

Dr. Yao Zhu is an attending urologist at Fudan University Shanghai Cancer Center and an Associate Professor in Oncology at Shanghai Medical College. He received his MD from Fudan University in 2006. After completing his internship, he started his residency in the Department of Urology at Fudan University Shanghai Cancer Center. He is certified by the Chinese Board of Urology and his practice focuses on managing urological malignancies. He is involved in several multicenter clinical trials and investigator-initiated clinical trials on genitourinary malignancies. His research is supported by grants from the National Nature Science Foundation of China.